Question to the Department of Health and Social Care:

To ask His Majesty's Government how many single technology appraisals of medicines conducted by the National Institute for Health and Care Excellence for (1) non-orphan medicines and (2) orphan medicines resulted in (a) a positive recommendation, (b) an optimised recommendation, (c) a recommendation for managed access, (d) a negative recommendation and (e) termination in each financial year since 2022–23.

The number and percentage of orphan and non-orphan medicines appraised by the National Institute of Health and Care Excellence through its Technology Appraisal and Highly Specialised Technology work programmes is presented in the attached table. Orphan drugs are drugs that are intended for the treatment or prevention of rare and severe diseases, that provide significant benefit to those affected by the condition.